press release

Saxenda® demonstrated similar efficacy and safety profile across obesity severity stages

VANCOUVER, May 3, 2016 /CNW/ - Today, pooled results from the SCALE™ Obesity and Prediabetes, and SCALE™ Diabetes trials were presented at the 13th International Congress on Obesity (ICO). This post-hoc analysis demonstrated that at 56 weeks, people with obesity or who were overweight with comorbidities and treated with Saxenda®, as an adjunct to a reduced-calorie diet and increased physical activity, had a generally consistent effect on weight loss and certain weight related risk factors across baseline Edmonton Obesity Staging System (EOSS) scores. The EOSS is a disease staging system, which ranks severity of obesity based on clinical assessment of weight-related health problems, mental health and physical function.

At 56 weeks, greater weight loss was seen in people with obesity or who were overweight, with or without type 2 diabetes, treated with Saxenda® compared to placebo consistently across all baseline EOSS scores. Additionally, improvements in cardiometabolic risk factors (including HbA1c, systolic blood pressure (SBP) and lipid parameters) and physical function were greater in those treated with Saxenda® compared to placebo, again, consistently across all baseline EOSS scores.

For this analysis, individuals were assigned a baseline EOSS score ranging from 0-4, based on the available data on obesity-related comorbidities. An EOSS score of 0 indicated no obesity-related comorbidities or risk factors, whereas a score of 4 indicated severe disability due to obesity-related comorbidities or risk factors.

Rather than using BMI, the traditional measure of obesity, we developed the Edmonton Obesity Staging System as a tool to describe the overall health of people with obesity or who are overweight with the aim of better supporting weight-management decisions in clinical practice. said Dr Arya Sharma, University of Alberta, Canada and SCALE™ clinical trial investigator. In this analysis, we saw that Saxenda® led to weight loss and improvements of weight-related comorbidities in people with obesity regardless of the severity of their disease.

Saxenda® was generally well tolerated and observed side effects were in line with previous liraglutide trials. Across EOSS scores, rates of overall adverse events were similar. Pulse rate increased with Saxenda® (1.9–2.6 bpm) vs placebo (-3.9–0.9 bpm treatment difference 2.0–6.5 bpm, p 0.05).

About obesity

Obesity is a disease that requires long-term management. It is associated with many serious health consequences and decreased life-expectancy. Obesity-related comorbidities include type 2 diabetes, heart disease, obstructive sleep apnoea (OSA) and certain types of cancer. It is a complex and multi-factorial disease that is influenced by genetic, physiological, environmental and psychological factors.
The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In 2014, 13 per cent of adults, or approximately 600 million adults, were living with obesity.\textsuperscript{10} In Canada, approximately 25 per cent of adults, equivalent to approximately 6.5 million people, live with obesity.\textsuperscript{11} Estimates of the economic burden of obesity in Canada range from $4.6 billion to $7.1 billion annually.\textsuperscript{12}

**About the Edmonton Obesity Staging System (EOSS)**

The EOSS ranks people with obesity on a 5-point scale, based on severity of obesity based on clinical assessment of weight-related health problems, mental health and quality of life:

- **EOSS score '0'** = no signs of obesity-related risk factors, physical symptoms, psychological symptoms, or functional limitations
- **EOSS score '1'** = mild obesity-related physical symptoms, psychological, or functional limitations
- **EOSS score '2'** = presence of established obesity-related comorbidities (such as hypertension, type 2 diabetes, sleep apnoea, osteoarthritis) requiring medical intervention, moderate psychological symptoms or limitations in activities of daily living
- **EOSS score '3'** = significant obesity-related comorbidities with end-organ damage such as heart failure, stroke, significant psychological symptoms, functional limitations or impairment of well-being
- **EOSS score '4'** = severe end-stage disease from obesity-related comorbidities, severely disabling psychological symptoms, functional limitations or impairment of well-being\textsuperscript{2}

**About Saxenda®**

Saxenda® (liraglutide 3 mg) is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97 per cent similarity to naturally occurring human GLP-1, a hormone that is released in response to food intake.\textsuperscript{13} Like human GLP-1, Saxenda® regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake. As with other GLP-1 receptor agonists, Saxenda® stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner.\textsuperscript{3} These effects can lead to a reduction of fasting and post-prandial blood glucose. Saxenda® was evaluated in the SCALE™ (Satiety and Clinical Adiposity – Liraglutide Evidence) phase 3 clinical trial program.

In Canada, Saxenda® is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m\textsuperscript{2} or greater (obese), or 27 kg/m\textsuperscript{2} or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) who have failed a previous weight management intervention.\textsuperscript{14}
Guidance is given in all labels that treatment with Saxenda® should be discontinued if a specific threshold of weight loss has not been achieved after a certain period of time.

About the SCALE™ clinical development program
Novo Nordisk’s phase 3 development program, called SCALE™, investigates liraglutide 3 mg for weight management. SCALE™ (Satiety and Clinical Adiposity – Liraglutide Evidence) consists of four, placebo-controlled, multinational trials called: SCALE™ Obesity and Prediabetes, SCALE™ Diabetes, SCALE™ Sleep Apnoea and SCALE™ Maintenance. The trials include more than 5,000 people who are overweight (BMI ≥27 kg/m2) with comorbidities such as hypertension, dyslipidaemia, obstructive sleep apnoea (OSA), or type 2 diabetes, or who have obesity (BMI ≥30 kg/m2), with or without comorbidities. The studies all involved a reduced-calorie diet and increased physical activity.

Key results from all trials in the SCALE™ clinical development program have been published, with further data expected to be presented and published throughout 2016.

About Novo Nordisk
Novo Nordisk Canada is an affiliate of Novo Nordisk A/S, a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries.

Novo Nordisk's company history has deep Canadian roots, with company founders Marie and August Krogh traveling to Toronto in 1922 to meet with Banting, Best, Collip and MacLeod to discuss the insulin preparation. Novo Nordisk would become the first company in Europe to produce insulin in 1923.

Novo Nordisk Canada employs approximately 280 people at its head office in Mississauga and across Canada. The company is listed as one of Canada's Top 100 Employers for 2016 and has also been awarded the distinction of being a Top GTA Employer since 2008. For more information, visit www.novonordisk.ca or follow us on Twitter @NovoNordiskCA.

References

1. Sharma A FN, Padwal R, Skøth T, Jensen C, Kushner R. The efficacy and safety of liraglutide 3.0 mg for weight management are similar across baseline Edmonton obesity staging system (eos) categories: Post hoc analysis at 56 weeks. International Congress on Obesity (ICO) 2016.
Novo Nordisk Marks 90 Years of Innovating Diabetes Care

Denmark's Crown Prince Couple Help Celebrate Canadian, Danish Partnership, Marking Novo Nordisk's 30 Years in Canada

MISSISSAUGA, ON, Sept. 18, 2014 /CNW/- Danish-based pharmaceutical company Novo Nordisk, in collaboration with the Royal Danish Consulate General and the Canadian Diabetes Association (CDA), is hosting “Innovation in Diabetes Care: 90 Years and Beyond” at the MaRS Discovery District today, to highlight the significant contribution Canada has made to diabetes care, and the collaborative spirit and innovation Canadian and Danish researchers have shared over the past 90 years. The event will honour the partnership between Denmark and Canada, through presentations and a panel discussion around the evolution of diabetes care.

"Today, we’re bringing together global and local stakeholders who have all contributed to improving diabetes care - from the Canadian discovery of insulin in 1921 to the Danish advancements in diabetes treatments and devices to the CDA’s Diabetes Charter for Canada that is setting the new standard of care today," said Vince Lamanna, President, Novo Nordisk Canada Inc. "The key to a better future for people living with diabetes is to foster these collaborations, and together, continue to drive innovation and education."

Hosted by Vince Lamanna, speakers will include Dr. Ronald Goldenberg, Clinical Endocrinologist, North York General Hospital; Lars Rebien Sørensen, President & CEO, Novo Nordisk A/S; Rick Blickstead, President & CEO, CDA and Dr. Janet Hux, Chief Science Officer, CDA.

Special guests include HRH the Crown Prince, HRH the Crown Princess and Niels Boel Abrahamsen, Danish Ambassador to Canada as part of a Danish trade mission to Canada.

"The Royal Danish Consulate General is proud to partner with Novo Nordisk," said Erik Landriault, Trade Advisor, Healthcare and Life Sciences, Royal Danish Consulate General. "By focusing on innovation and bringing patient care into the community, Novo Nordisk is helping to better manage chronic diseases like diabetes, improve the lives of Canadians and make Canada’s healthcare system more sustainable."

More than three million Canadians are living with diabetes, a number that is expected to increase to 4.8 million by 2024.i To mark this celebration, guests will be encouraged to sign the Diabetes Charter for Canada, which outlines what people with diabetes can and should expect from themselves and others in the diabetes community.

---


SOURCE Novo Nordisk Canada Inc.

For further information: Media: Jeremy Brace, 1 416 454 7556, jmbc@novonordisk.com; Amanda Federchuk, 1 416 486 7231, amanda.federchuk@gcicanada.com; Katrine Sperling, +45 4442 6718, krsp@novonordisk.com; Åsa Josefsson, +45 3079 7708, aajf@novonordisk.com; Investors: Peter Hugreffe Ankersen, +45 3075 9085, phak@novonordisk.com; Melanie Raouzeos, +45 3075 3479, mrz@novonordisk.com; Daniel Bohsen, +45 3079 6376, dabo@novonordisk.com; Kasper Veje, +45 3079 8519, kpvj@novonordisk.com